BCL-2 is dispensable for thrombopoiesis and platelet survival

MA Debrincat, I Pleines, M Lebois , RM Lane, ML Holmes, J Corbin, CJ Vandenberg, WS Alexander, AP Ng, A Strasser, P Bouillet, M Sola-Visner, BT Kile, EC Josefsson

Research output: Contribution to journalArticleResearchpeer-review

42 Citations (Scopus)

Abstract

Navitoclax (ABT-263), an inhibitor of the pro-survival BCL-2 family proteins BCL-2, BCL-XL and BCL-W, has shown clinical efficacy in certain BCL-2-dependent haematological cancers, but causes dose-limiting thrombocytopaenia. The latter effect is caused by Navitoclax directly inducing the apoptotic death of platelets, which are dependent on BCL-XLfor survival. Recently, ABT-199, a selective BCL-2 antagonist, was developed. It has shown promising anti-leukaemia activity in patients whilst sparing platelets, suggesting that the megakaryocyte lineage does not require BCL-2. In order to elucidate the role of BCL-2 in megakaryocyte and platelet survival, we generated mice with a lineage-specific deletion of Bcl2, alone or in combination with loss of Mcl1 or Bclx. Platelet production and platelet survival were analysed. Additionally, we made use of BH3 mimetics that selectively inhibit BCL-2 or BCL-XL. We show that the deletion of BCL-2, on its own or in concert with MCL-1, does not affect platelet production or platelet lifespan. Thrombocytopaenia in Bclx-deficient mice was not affected by additional genetic loss or pharmacological inhibition of BCL-2. Thus, BCL-2 is dispensable for thrombopoiesis and platelet survival in mice.

Original languageEnglish
Article numbere1721
Number of pages8
JournalCell Death & Disease
Volume6
Issue number4
DOIs
Publication statusPublished - 16 Apr 2015
Externally publishedYes

Cite this